| Code | CSB-RA836186MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to elezanumab, designed for research applications targeting repulsive guidance molecule A (RGMA). RGMA is a glycosylphosphatidylinositol-anchored protein that functions as an axonal growth inhibitor by binding to neogenin receptors. It plays a critical role in neural development and axon guidance during embryogenesis. In the adult central nervous system, RGMA contributes to the inhibition of axonal regeneration following injury and has been implicated in neurodegenerative conditions. Elevated RGMA expression has been associated with multiple sclerosis, spinal cord injury, and stroke, where it limits neuronal repair and functional recovery.
Elezanumab is a humanized IgG1 monoclonal antibody that neutralizes RGMA activity, thereby promoting axonal growth and potentially enhancing neural repair mechanisms. This biosimilar antibody serves as a valuable tool for investigating RGMA-mediated signaling pathways, studying axon regeneration mechanisms, and exploring therapeutic strategies for neurological disorders characterized by impaired neural plasticity. It enables researchers to examine the role of RGMA in disease models and evaluate potential neuroprotective interventions.
There are currently no reviews for this product.